A pharmacogeneticist and neuromuscular geneticist by background with over 24 years at-the-bench and management experience in genetic sciences including 12 years industry experience in the integration of genetic data to drive drug development, Anthony Akkari is currently the Director of Pharmacogenetics and Neurogenetics at Cabernet Pharmaceuticals, a North Carolina-based company providing pharmacogenetics and project-management consultancy services to the pharmaceutical industry. Tony is responsible for the motor neurone disease program at Cabernet Pharmaceuticals having previously been responsible for a Type 2 diabetes pharmacogenetics program at Eli Lilly. Tony’s links with the Perron Institute to back to the 1990s when he completed a PhD in the institute under the supervision of Professor Nigel Laing and continue through his links with Steve Wilton and his research group.